Evidence map›Paper›PMID 41105630›Full record

ArticlePloS one2025

Investigating the HIV epidemic among Black gay and bisexual men in the Southern United States: Results of the HPTN 096 pilot cross-sectional assessment.

Chris Beyrer, Robert H Remien, Susan H Eshleman, Theresa R Gamble, Jean De Dieu Tapsoba, Rita L Labbett, Philip A Sullivan, Oliver Laeyendecker, Peter L Anderson, Devang Agravat and 13 more

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Chris BeyrerDuke Global Health Institute, Duke University, Durham, North Carolina, United States of America.ORCID https://orcid.org/0000-0003-0665-9124
Robert H RemienNew York State Psychiatric Institute and Columbia University, New York, New York, United States of America.ORCID https://orcid.org/0000-0002-4491-5275
Susan H EshlemanJohns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.ORCID https://orcid.org/0000-0002-4587-791X
Theresa R GambleHIV Prevention Trials Network Leadership and Operations Center, Durham, North Carolina, United States of America.ORCID https://orcid.org/0000-0002-2515-0828
Jean De Dieu TapsobaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.ORCID https://orcid.org/0000-0001-7453-4329
Rita L LabbettHIV Prevention Trials Network Leadership and Operations Center, Durham, North Carolina, United States of America.ORCID https://orcid.org/0009-0000-1854-3677
Philip A SullivanJohns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Oliver LaeyendeckerDivision of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.ORCID https://orcid.org/0000-0002-6429-4760
Peter L AndersonDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences. University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States of America.
Devang AgravatVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
James P HughesVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.ORCID https://orcid.org/0000-0001-5034-3157
Daniel D DriffinHIV Prevention Trials Network 096 Community Advisory Board, Atlanta, Georgia, United States of America.ORCID https://orcid.org/0009-0003-6735-4145
Craig S HutchinsonHIV Prevention Trials Network Black Caucus, Columbia, Washington, United States of America.
Christopher Hucks-OrtizHIV Prevention Trials Network Black Caucus, Columbia, Washington, United States of America.
Maurice AdairAID Upstate, Greenville, South Carolina, United States of America.
Melissa CurryAbounding Prosperity, Dallas, Texas, United States of America.
Shakita Brooks JonesCentral Alabama Alliance, Resource & Advocacy Center, Montgomery, Alabama, United States of America.ORCID https://orcid.org/0009-0004-0290-9186
Ian L HaddockThe Normal Anomaly, Houston, Texas, United States of America.ORCID https://orcid.org/0009-0008-7392-2600
Donte BoydThe Ohio State University, College of Social Work, Columbus, Ohio, United States of America.
Dale R BurwenAffiliation at the time the study was conducted: Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America.
Anna Satcher JohnsonDivision of HIV Prevention, National Center for HIV, Viral Hepatitis, Sexually Transmitted Disease and Tuberculosis Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
LaRon E NelsonSchool of Nursing, Yale University, New Haven, Connecticut, United States of America.
HPTN 096 pilot study team

Funding

LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
NIAID NIH HHS UM1 AI068613
6 · The paper itself

Abstract

backgroundThe HIV Prevention Trials Network (HPTN) 096 study was designed to address the markedly higher rates of HIV incidence among Black men who have sex with men (MSM) in the Southern United States (US). A cross-sectional assessment was conducted during the pilot phase of the study to determine its feasibility and collect key HIV-related metrics for the study population. METHODS AND

findingsFour hundred and twenty-two Black MSM, ≥ 15 years old and living in the four pilot communities (Dallas, TX; Houston, TX; Montgomery, AL; Greenville, SC), were enrolled via starfish sampling into the cross-sectional assessment. Each participant completed two questionnaires and had blood samples collected at a single study visit. Laboratory testing was performed to determine HIV status and use of oral pre-exposure prophylaxis (PrEP). HIV drug resistance and viral suppression were also assessed for two of the four pilot communities (Dallas and Houston). Categorical variables were summarized using frequency and percentage. Continuous variables were summarized using mean, standard deviation, median and interquartile range. Univariable and multivariable logistic regression models were used to assess various associations. HIV status was determined for 403 of the 422 participants (95.5%); 212 (52.6%) men were living with HIV, including one with acute HIV. For these participants, 163 (76.9%) reported that they were in HIV care. In Dallas and Houston, 71 of the 101 living with HIV (70.3%) were virally suppressed. Of the 191 not living with HIV, 57 (29.8%) reported ever taking PrEP, 41 (21.5%) reported being currently on PrEP, and eight (4.2%) reported never having heard of PrEP. PrEP use was documented through laboratory testing in 36 (19.1%) of 188 participants tested; of the 41 participants reporting current PrEP use, five did not have laboratory evidence of PrEP use.

conclusionDuring the pilot, we successfully recruited Black MSM using starfish sampling and demonstrated the feasibility of collecting primary study outcomes using a cross-sectional assessment. We found a high burden of HIV and those living with HIV had only a moderate rate of viral suppression. In addition, PrEP use was uncommon among the men living without HIV. Reducing HIV incidence in Black MSM remains a key element to addressing the HIV epidemic in the US.

Indexed as

BisexualityBlack or African AmericanEpidemicsHIV InfectionsHomosexuality, MaleAdolescentAdultCross-Sectional StudiesHumansIncidenceMaleMiddle AgedPilot ProjectsPre-Exposure ProphylaxisUnited StatesYoung Adult

Identifiers

PMID41105630
PMCPMC12533853

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.